Arbutus Biopharma Corp Files 8-K

Ticker: ABUS · Form: 8-K · Filed: May 22, 2024 · CIK: 1447028

Arbutus Biopharma Corp 8-K Filing Summary
FieldDetail
CompanyArbutus Biopharma Corp (ABUS)
Form Type8-K
Filed DateMay 22, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, financials, company-information

Related Tickers: ABUS

TL;DR

Arbutus Biopharma filed an 8-K on 5/22/24, updating corporate info and financials. No major news, just routine filing.

AI Summary

Arbutus Biopharma Corporation filed an 8-K on May 22, 2024, reporting other events and financial statements. The filing also notes the company's former name was Tekmira Pharmaceuticals Corp, with name changes occurring on June 7, 2011, and October 3, 2008. The principal executive offices are located at 701 Veterans Circle, Warminster, Pennsylvania.

Why It Matters

This 8-K filing serves as an official record of significant corporate events and financial disclosures for Arbutus Biopharma, providing transparency to investors and the market.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting corporate information and financial statements, with no indication of significant new risks or material adverse events.

Key Players & Entities

  • Arbutus Biopharma Corporation (company) — Registrant
  • Tekmira Pharmaceuticals Corp (company) — Former company name
  • May 22, 2024 (date) — Date of report
  • 701 Veterans Circle, Warminster, Pennsylvania (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing for Arbutus Biopharma Corporation?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of May 22, 2024.

What were Arbutus Biopharma Corporation's previous names?

Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp, with name changes occurring on June 7, 2011, and October 3, 2008.

Where are Arbutus Biopharma Corporation's principal executive offices located?

The principal executive offices of Arbutus Biopharma Corporation are located at 701 Veterans Circle, Warminster, Pennsylvania, 18974.

What is the Commission File Number for Arbutus Biopharma Corporation?

The Commission File Number for Arbutus Biopharma Corporation is 001-34949.

What is the SIC code for Arbutus Biopharma Corporation?

The Standard Industrial Classification (SIC) code for Arbutus Biopharma Corporation is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-05-22 06:00:18

Filing Documents

01. Other Events

Item 8.01. Other Events. On May 22, 2024, Arbutus Biopharma Corporation (the "Company") issued a press release announcing that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver (EASL) Congress 2024 taking place June 5 - 8, 2024 in Milan, Italy. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated May 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation Date: May 22, 2024 By: /s/ David C. Hastings David C. Hastings Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.